TSC22D4

Across TCGA pan-cancer cohorts, TSC22D4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TSC22D4 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TSC22D4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TSC22D4 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

GBM, LUAD, and LSCC are the cancer types where TSC22D4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.710	0.944	.003	18	view →
LUAD	DFS	Median	II,III,IV	0.234	0.821	.010	10	view →
LSCC	DFS	Median	All	0.704	0.884	.016	8	view →
PDAC	DFS	Median	II,III,IV	0.634	0.821	.006	7	view →
HNSC	OS	Tertile	III,IV	0.451	0.726	.006	6	view →
OV	DFS	Median	All	1.000	0.864	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TSC22D4–GBM (OS)

Open the GBM breakdown →